Expanding the therapeutic frontier in atherosclerosis

J Cardiovasc Pharmacol. 2013 Sep;62(3):237-8. doi: 10.1097/FJC.0b013e3182a18bea.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Animals
  • Atherosclerosis / prevention & control*
  • Drug Resistance*
  • Humans
  • Hypoalphalipoproteinemias / drug therapy*
  • Lipid Regulating Agents / therapeutic use*
  • Lipoproteins, HDL / blood*
  • Molecular Targeted Therapy*

Substances

  • Lipid Regulating Agents
  • Lipoproteins, HDL